Frequency Therapeutics

Yahoo Finance • 2 months ago

Korro to Present at the TD Cowen 46th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announ... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Korro Bio, Inc. is next on our list of best biotech stocks. TheFly reported on January 29 that H.C. Wainwright upgraded KRRO from Neutral to Buy with a $20 pr... Full story

Yahoo Finance • 5 months ago

Korro Bio stock fell after missing expectations in early stage KRRO-110 trial

[Colorful DNA helix] Stanislaw Pytel/DigitalVision via Getty Images Korro Bio (KRRO [https://seekingalpha.com/symbol/KRRO]) shares fell following results from its early-stage clinical trial of KRRO-110, aimed at treating patients with alp... Full story

Yahoo Finance • 6 months ago

These Were the Russell 2000 Stocks That Dominated In Q3 2025

The small cap-focused Russell 2000 index has spent years lagging behind the larger S&P 500 and Nasdaq 100 indexes, but in third-quarter 2025 it took a big leap back to parity with large caps. Thanks to interest-rate-cut bets and optimism... Full story

Yahoo Finance • 7 months ago

Korro to Participate in Upcoming Investor and Scientific Conferences

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of Septem... Full story

Yahoo Finance • 8 months ago

Top gaining Russell 2000 stocks as index close to strongest performance vs. large-caps

[Small Cap write on sticky notes isolated on Office Desk. Stock market concept] syahrir maulana/iStock via Getty Images The Russell 2000 (IMW) is close to its strongest relative performance compared to the S&P 500 (SP500 [https://seekinga... Full story

Yahoo Finance • 10 months ago

Novo Nordisk focused on biotech deals for cardiometabolic indications

[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer In the aftermath of several dea... Full story

Yahoo Finance • last year

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly... Full story

Yahoo Finance • last year

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration (FDA) Granted Orphan... Full story

Yahoo Finance • last year

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly... Full story

Yahoo Finance • last year

Korro to Present at the TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly p... Full story